U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H26O6
Molecular Weight 434.481
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LY-2300559

SMILES

CCCC1=C(OCC2=CC=C(C=C2)[C@H](O)C3=CC(=CC=C3)C(O)=O)C=CC(C(C)=O)=C1O

InChI

InChIKey=DWQVYDLTPMGYNE-DEOSSOPVSA-N
InChI=1S/C26H26O6/c1-3-5-22-23(13-12-21(16(2)27)25(22)29)32-15-17-8-10-18(11-9-17)24(28)19-6-4-7-20(14-19)26(30)31/h4,6-14,24,28-29H,3,5,15H2,1-2H3,(H,30,31)/t24-/m0/s1

HIDE SMILES / InChI
LY2300559 is a dual metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator and cysteinyl leukotriene receptor 1 (CysLTR1) antagonist. Eli Lilly was developing LY2300559 for the prevention of migraine. LY2300559 development has been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q14416
Gene ID: 2912.0
Gene Symbol: GRM2
Target Organism: Homo sapiens (Human)
50.0 nM [EC50]
Target ID: Q9Y271
Gene ID: 10800.0
Gene Symbol: CYSLTR1
Target Organism: Homo sapiens (Human)
22.0 nM [Ki]
PubMed

PubMed

TitleDatePubMed

Sample Use Guides

Phase 2 study in migraine prevention: 300 mg once daily, for 12 weeks
Route of Administration: Oral
Name Type Language
LY-2300559
Common Name English
LY2300559
Code English
3-((S)-(4-((4-ACETYL-3-HYDROXY-2-PROPYL-PHENOXY)METHYL)PHENYL)-HYDROXY-METHYL)BENZOIC ACID
Systematic Name English
BENZOIC ACID, 3-((S)-(4-((4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)METHYL)PHENYL)HYDROXYMETHYL)-
Systematic Name English
Code System Code Type Description
FDA UNII
Z572ZBT8XL
Created by admin on Sat Dec 16 10:14:05 GMT 2023 , Edited by admin on Sat Dec 16 10:14:05 GMT 2023
PRIMARY
CAS
889116-06-7
Created by admin on Sat Dec 16 10:14:05 GMT 2023 , Edited by admin on Sat Dec 16 10:14:05 GMT 2023
PRIMARY
CLINICAL_TRIALS.GOV
LY-2300559
Created by admin on Sat Dec 16 10:14:05 GMT 2023 , Edited by admin on Sat Dec 16 10:14:05 GMT 2023
PRIMARY Official Title: A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study of LY2300559 in Patients With Migraine
PUBCHEM
11611800
Created by admin on Sat Dec 16 10:14:05 GMT 2023 , Edited by admin on Sat Dec 16 10:14:05 GMT 2023
PRIMARY
DRUG BANK
DB13016
Created by admin on Sat Dec 16 10:14:05 GMT 2023 , Edited by admin on Sat Dec 16 10:14:05 GMT 2023
PRIMARY